CLINICAL STUDY ON 7432-S, A NEW PERORAL ANTIBIOTICS, IN URINARY TRACT INFECTION

Abstract

7432-S, a newly developed cephem, was orally administered at 100 mg twice a day for 3-5 days to 11 patients with urinary tract infection (acute uncomplicated cystitis 5 cases, acute uncomplicated pyelonephritis 1, chronic complicated cystitis 4, chronic complicated pyelonephritis 1).
The clinical efficacy of uncomplicated UTI was excellent in 5 cases and poor in 1 by the physicians evaluation and excellent in 4 by the Japanese UTI Drug Evaluation Criteria.(Two of 6 cases were not suitable for evaluation by the UTI-Criteria). The efficacy rate was 83.3% by the physician's and 100% by the UTI evaluation.
The clinical efficacy in uncomplicated UTI was evaluated in 4 cases, the rate being 75% by either, criteria (excellent 1, good 2, poor 1).
No subjective or objective side effects were not found.